Home › Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC
 

Keywords :   


Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC

2015-02-14 13:04:00| Biotech - Topix.net

Eisai Inc. announced today that the U.S. Food and Drug Administration approved the company's receptor tyrosine kinase inhibitor LENVIMA for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer . LENVIMA was approved following a priority review by the FDA, which is designated for drugs the FDA believes have the potential to provide a significant improvement in the treatment of a serious condition.

Tags: treatment approval announces fda

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
19.05Fujitsu sacked boss at height of Horizon scandal
19.05Atlantic Tropical Weather Outlook
19.05Eastern North Pacific Tropical Weather Outlook
18.05Eastern North Pacific Tropical Weather Outlook
18.05Atlantic Tropical Weather Outlook
18.05M&S website and app hit by technical issue
18.05Eastern North Pacific Tropical Weather Outlook
18.05Atlantic Tropical Weather Outlook
More »